Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study

Insulin Resistance Clinical Trial

— GENIE  

Official title:

Epigenomics in Insulin Resistance Associated Overactive Bladder.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03057158
• Other study ID #: Pro00079255
• Secondary ID: 302-0870
• Status: Completed
• Start date: May 1, 2017
• Est. completion date: March 11, 2020

Study information

• Verified date: November 2019
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Millions of women suffer from overactive bladder, and the changes in bladder function affect their quality of life. The study team believes that it needs to be better understand why women get overactive bladder in the first place so that better treatments can eventually be offered.

The purpose of this study is to determine why women with insulin resistance are more likely to get overactive bladder. Overactive bladder is a type of bladder control problem that can cause some women to have bladder leakage. This problem is more common in women with diabetes and pre-diabetes, but it isn't known why.

Description:

The methylation of cytosines in CpG sites can have profound effects on the ability of genes to be transcribed. To clarify and distinguish the specific methylation changes responsible for overactive bladder (OAB) in those with insulin resistance (IR), the investigator will compare three well-characterized groups of women: 1) OAB and IR; 2) IR only (no OAB); and 3) OAB only (no IR). In this proposal the investigator is only studying women since they are more likely to be affected by OAB with incontinence, the investigator wants to study pure cohorts of patients, and because this is the clinical population cared for by the primary investigator. The plan for future investigations is to apply these findings to broader groups to better understand gender and racial differences.

In Specific Aim 1, the investigator will conduct an epigenome-wide association study (EWAS) study, followed by targeted validation studies to determine whether CpG sites throughout the genome are differentially methylated in well-characterized and matched cohorts, while controlling for the effects of insulin-resistance. In Specific Aim 2, the investigator will assess for differential expression of candidate loci in relation to methylation. RNA-sequencing (RNA-seq) will be used to establish differences in the transcriptome between extreme phenotypes of OAB+IR and OAB alone. The investigator will then use quantitative polymerase chain reaction (qPCR) to validate expression differences in all cohorts, and to confirm differences in candidate loci that are confirmed in experiments from Aim 1. The investigator will proceed with bioinformatic pathway analyses to identify the function and interdependence of genes with altered expression and altered methylation profiles. In Specific Aim 3, the investigator will determine whether expression (mRNA and protein) differences in voided urine cells are also exhibited in biopsied bladder mucosa. The investigator will use targeted assays to confirm similar methylation profiles and gene expression in voided cells and bladder biopsies. The investigator will also compare protein expression of candidate loci such as EXOC6, ZFC3H1, RPS6KA2, and SPON2 proteins, if confirmed in other Aims, between cohorts. When the proposed studies have been completed, it is the expectation that the investigator will have functionally characterized the methylation changes that the investigator preliminarily identified in IR associated OAB.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 257
• Est. completion date: March 11, 2020
• Est. primary completion date: March 9, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Women over the age of 18.

• Urgency incontinence (at least 3 times per week) for > 3months

• History of elevated A1C or Type II diabetes (UUI+IR and IR only groups)

• Non-pregnant

• At least 6 months since most recent childbirth

Exclusion criteria:

• Active pregnancy, or within 6 months of childbirth

• Breastfeeding

• Proteinuria (defined as >1+ protein on urine dipstick in the absence of infection)

• Gross hematuria (in the absence of UTI)

• Type I diabetes mellitus

• Type II diabetes with chronic renal impairment (Cr >1.5)

• Chronic renal disease (includes vasculitis, focal segmental glomerulosclerosis, lupus nephritis, polycystic kidney disease, nephropathy)

• Receiving chemotherapy or radiation for malignancy

• Taking one of the following drugs that influence DNA methylation: hydralazine, procainamide, methotrexate, valproic acid, tamoxifen, raloxifene, letrozole, anastrozole (Arimidex), or exemestane (Aromasin)

• Any history of urinary tract malignancy (bladder, urethra, ureter, kidney)

• Intradetrusor Botox injection within the prior 12 months

Related Conditions & MeSH terms

• Insulin Resistance
• Overactive Bladder
• Urinary Bladder, Overactive

Locations

Country	Name	City	State
United States	Duke University	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportions of differentially methylated CpG sites between cohorts, from Illumina EPIC chip	Extract DNA from voided urine cells and compare human DNA using Illumina EPIC Methylation Chip to assess methylation of different sites across the genome	2 years
Secondary	Compare methylation between DNA extracted from voided urine cells and bladder urothelial biopsies	DNA will be extracted from voided urine cells and from urothelial biopsies in the same patients. Targeted methylation assays will be used to compare methylation sites between sample types	2 years
Secondary	Gene expression (from RNA-sequencing)	Compare mRNA recovered from bladder biopsies between women in 3 cohorts (Urgency incontinence only, insulin resistance only, urgency incontinence with insulin resistance)	2 Years
Secondary	Gene expression (from PCR)	Compare expression of candidate genes between cohorts by using polymerase chain reaction (PCR) and extracted RNA	2 Years